Dr. Neel recognized that the parents of children with thalassemia major had thalassemia minor with one beta thalassemia gene. When these parents had children, they had a 25% chance of having a thalassemia major child (with both genes for beta thalassemia), a 50% chance of having children with...
Thalassemia carrier screeningArtificial neural networksDecision treesThe most effective way to combat 尾-thalassemias is to prevent the birth of children with thalassemia major. Therefore, a cost-effective screening method is essential to identify 尾-thalassemia traits (BTT) and differentiate normal ...
India, Southern China, and the Far East as well as countries along the north coast of Africa and in South America. The highest carrier frequency is reported in Cyprus (14%), Sardinia (10.3%), and Southeast Asia [1]. The high gene frequency of beta-thalassemia in these regions is most ...
There is a 1:4 chance of having a child with Sβ-Thalassemia if one of the parents has HbS mutation and the other parent is a carrier of β-thalassemia [2]. The prevalence of Sβ-thalassemia was reported to be less than one-third to zero percent of sickle-cell cases [3, 4]. ...
Significance of borderline HbA2 levels in β thalassemia carrier screening Article Open access 30 March 2022 Abnormal hemoglobin anti-Lepore Hong Kong compound with β0-thalassemia ameliorate thalassemia severity when co-inherited with α-thalassemia Article Open access 20 March 2024 A novel compou...
Beta-thalassemia stands as an autosomal recessive disorder that occurs as a result of a defect in the beta-globin chain synthesis of hemoglobin. Oxidative stress has a crucial role in the β-thalassemia pathophysiology. It occurs due to erythroid expansi
Carrier screening and prenatal diagnosis have been widely performed in China to prevent the birth of children with homozygous α0‐and β-thalassemias. Mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) are the most commonly used indicators for β-thalassemia screening, with low va...
In some embodiments, the therapeutic gene is used to genetically correct sickle cell anemia or β-thalassemia; or reduce symptoms thereof. In some embodiments, the nucleic acid sequence encoding the micro-RNA based shRNA targeting the HPRT gene has a sequence having at least 80% identity to ...
This mutation did not show any significant effect on the change of blood indices, neither in healthy individuals nor in sickle cell trait and beta-thalassemia carriers. Therefore, there is no need to take more notice of anti 3.7 mutation in beta-thalassemia carriers is opposed with some studies...
When red blood cell indexes reveal a possibility of a g -thalassemia carrier state with the symptoms of hemolytic anemia, HS should be considered.doi:10.1080/08880010290097431Akar, NejatG?k?e, HafizeTaylor & FrancisEuropean Paediatric Haematology & Oncology...